Forterre Gael 4

What Happened Forterre Gael, Chief Commercial Officer of VolitionRx Ltd (VNRX), was granted 149,000 restricted stock units (RSUs) on February 26, 2026. The award was issued in lieu of cash compensation and shows an acquisition price of $0.00 on the Form 4. The RSUs are earned in twelve approximately equal monthly installments beginning March 1, 2026 and, once earned, remain subject to additional time-based vesting that will occur in a single installment on February 26, 2027. Upon vesting and settlement, Mr. Forterre will receive a number of common shares equal to the RSUs earned and vested.

Key Details

• Transaction type: Award/Grant (Form 4 code A) — 149,000 RSUs granted.
• Transaction date: February 26, 2026; Form 4 filed February 27, 2026 (appears timely).
• Reported acquisition price: $0.00 (awarded in lieu of cash); no cash paid at grant.
• Vesting schedule: Earned monthly in 12 approx. equal installments starting Mar 1, 2026; after earning, additional time-based vesting in one installment on Feb 26, 2027; continued service required for earning/vesting.
• Shares owned after transaction: Not specified on this filing.
• Footnote re holdings: Certain common shares are managed by Armorica Partners, LLC. Mr. Forterre is the managing director and sole shareholder of Armorica Partners and has voting and dispositive control over those shares but disclaims beneficial ownership except for his pecuniary interest.

Context RSU grants are a form of compensation and do not involve an out-of-pocket purchase by the insider; they represent future entitlement to shares if earning and vesting conditions are met. This type of filing documents compensation arrangements rather than an immediate market purchase or sale and should be viewed as compensation-related, not a direct buying/selling signal.